title: Temozolomide may induce therapy-related acute lymphoblastic leukaemia.
authors.forename: Mizuki
authors.initials: M
authors.lastname: Ogura
authors.forename: Tomoki
authors.initials: T
authors.lastname: Todo
authors.forename: Minoru
authors.initials: M
authors.lastname: Tanaka
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Nannya
authors.forename: Motoshi
authors.initials: M
authors.lastname: Ichikawa
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Nakamura
authors.forename: Mineo
authors.initials: M
authors.lastname: Kurokawa
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005910:Glioma / Q000150:complications / Q000628:therapy; D006801:Humans; D016609:Neoplasms, Second Primary; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced*; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide